Literature DB >> 16362789

A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.

Andrea Hille1, Nadja Töws, Heinz Schmidberger, Clemens F Hess.   

Abstract

BACKGROUND AND
PURPOSE: Rectal toxicity following external-beam irradiation of prostate cancer correlates with the exposed percentage of rectal volume. Recently, it has been recommended to reduce the volume of the seminal vesicles that should be included in the clinical target volume (CTV). The purpose of this study was to quantitatively assess the impact of this CTV reduction on the expected rectal and bladder dose sparing. PATIENTS AND METHODS: 14 patients with localized prostate cancer undergoing external-beam radiotherapy were investigated. The prostate, the prostate + entire seminal vesicles, or the prostate + proximal seminal vesicles were delineated as CTV. Treatment plans were generated and compared concerning rectum and bladder dose-volume histograms (DVHs).
RESULTS: The exposure of rectum and bladder volume was significantly lower in case of irradiation of the prostate only compared to inclusion of the proximal or entire seminal vesicles into the CTV. The reduction of the CTV from prostate + entire seminal vesicles to prostate + proximal seminal vesicles led to a significant reduction of the rectal and bladder dose exposure.
CONCLUSION: Reduction of the CTV to the prostate only, or to the prostate + proximal seminal vesicles led to significant rectal and bladder dose sparing compared to irradiation of the prostate + entire seminal vesicles. In patients with a higher risk for seminal vesicles involvement, irradiation of the prostate + proximal seminal vesicles should be preferred. In case of a need for irradiation of the entire seminal vesicles, patients should be informed about a higher risk for chronic rectal toxicity and, possibly, for bladder complications.

Entities:  

Mesh:

Year:  2005        PMID: 16362789     DOI: 10.1007/s00066-005-1452-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  4 in total

1.  Patient positioning variations to reduce dose to normal tissues during 3D conformal radiotherapy for high-risk prostate cancer.

Authors:  K Czigner; P Agoston; G Forgács; M Kásler
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

2.  Target volume coverage and dose to organs at risk in prostate cancer patients. Dose calculation on daily cone-beam CT data sets.

Authors:  P Hüttenrauch; M Witt; D Wolff; S Bosold; R Engenhart-Cabillic; J Sparenberg; H Vorwerk; K Zink
Journal:  Strahlenther Onkol       Date:  2014-01-16       Impact factor: 3.621

3.  Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer.

Authors:  Michael Pinkawa; Marc D Piroth; Karin Fischedick; Richard Holy; Jens Klotz; Sandra Nussen; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

4.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.